The surface protein receptor tyrosine kinase (TK) and epidermal growth factor receptor (EGFR) are targets for many drugs, particularly for treating lung cancer.1 Mutation and alteration of EGFR in the cell lead to the development of NSCLC. This evidence concerns the gene EGFR and lung cancer.